INTRODUCTION
============

Cancer patients are prone to depression, with a 22%--29% median prevalence rate ([@b21-jer-15-2-264]). Intuitionally, many factors like fear of cancer, economic burden, treatment-related physical and psychotic burden, and functional deterioration might have an effect on patients' depression. Considering the fact that one of the cancers with the highest incidence in men around the world is the prostate cancer (PCa), research regarding the relationship between PCa and depression is far-reaching. Like other malignancies, it has been known that PCa is related with depression ([@b5-jer-15-2-264]; [@b24-jer-15-2-264]). A previous report found that almost 30% of PCa patients met general distress status in the clinical field ([@b3-jer-15-2-264]). However, the main research interest concerning depression in PCa patients is usually related to advanced PCa with androgen deprivation treatment (ADT) because many studies have suggested that there is a positive association between ADT and depressive mood ([@b6-jer-15-2-264]; [@b17-jer-15-2-264]; [@b27-jer-15-2-264]).

Localized PCa has a high success rate of treatment and 5-year survival rate ([@b29-jer-15-2-264]), and there are some reports that early localized PCa patients have a low level of psychopathology ([@b1-jer-15-2-264]), therefore the interest regarding the psychopathologic effect in this population has been relatively low. However, recently contradictory research has been published stating that newly diagnosed PCa is associated with psychotic distress and also increased the risk of suicide by 2.5 times within 1 year of diagnosis, compared to the general population ([@b7-jer-15-2-264]), and persistently elevated the risk thereafter ([@b7-jer-15-2-264]; [@b19-jer-15-2-264]). At the same time the interest in the quality of life (QoL) has elevated, generating a recent increase in the necessity for research regarding the relationship between localized PCa and depression. Furthermore, although the most common treatment for localized PCa is radical prostatectomy (RP), the fact is, little is known about the relationship between RP for PCa and emotional stress, including depression ([@b31-jer-15-2-264]). Accordingly, psychopathological status is less frequently treated than systemic and physical pathologic status ([@b12-jer-15-2-264]). Understanding the relationship between depressive mood and PCa is essential for providing proper treatment and support for PCa patients because some studies have suggested that depression is related with QoL as well as with the cancer survival rate ([@b9-jer-15-2-264]; [@b25-jer-15-2-264]).

Some potential factors known to have an effect on depression in patients with localized PCa after RP include age, obesity, cancer stage, serum testosterone, underlying disease, lower urinary tract symptoms (LUTS), sexual function, and QoL ([@b18-jer-15-2-264]; [@b26-jer-15-2-264]; [@b28-jer-15-2-264]). Likewise, with the relationship between PCa and depressive mood, there is a shortage of studies exploring factors influencing depressive mood in PCa patients and patterns in that relationship.

The study objective is to determine the pattern of depressive mood in patients who underwent RP for localized PCa and the diverse factors that may affect depressive mood in the early period after the surgery.

MATERIALS AND METHODS
=====================

Participants
------------

This present study was performed with a total of 30 patients who were newly diagnosed with localized PCa and underwent RP in our hospital. The principles of the Helsinki Declaration were followed in lieu of formal ethics committee approval and all study processes were approved by the Gachon University Institutional Review Board (approval number: GCIRB 2017-296).

The study period was from September 2017 to August 2018, including a total of 30 patients (aged 68.03±6.1 years) who were diagnosed with localized PCa and underwent RP within 1 month of diagnosis. All of the patients had no history of psychopathological disease including depression. The participation in this study was voluntary and all the patients submitted informed consent. Evaluations included body mass index (BMI), initial serum prostate specific antigen, serum testosterone, and assessment for the underlying disease.

Functional measurement
----------------------

Three questionnaires were used to assess the study parameters: (a) the International Prostatic Symptom Score (IPSS) & QoL, (b) the International Index of Erectile Function (IIEF), and (c) Beck depression inventory (BDI). IPSS and QoL is a questionnaire used to evaluate LUTS and QoL which shows both compatibility and reliability ([@b2-jer-15-2-264]). IIEF is a widely used multi-dimensional self-reported questionnaire for the evaluation of male sexual function and has been regarded as the gold-standard treatment outcome measurement for erectile dysfunction ([@b23-jer-15-2-264]). BDI is widely used self-reported questionnaire that evaluates the degree of depressive symptoms and it has been proven to have both reliability and sensitivity ([@b20-jer-15-2-264]).

IPSS, QoL, IIEF, and BDI were assessed twice, within 1 month after RP and again 3 months later. All questionnaires were answered using a self-recorded method under the assistance of a trained nurse.

Statistical analysis
--------------------

Basic demographic data, laboratory results, and questionnaire data were analyzed statistically. The comparison of parameters between initial assessment and follow-up assessment was evaluated using paired *t*-tests. The Kolmogorov--Smirnov test was used to verify the normality of distribution of continuous variables. Correlation between BDI score and other variables such as age, BMI, testosterone level, IPSS, QoL, IIEF and underlying disease was evaluated using the Pearson correlation coefficient. Inter-scale correlation between BDI and each subscale for evaluation of the degree of correlation was also verified using the Pearson correlation coefficient. To assess a possible predictive value of variables on the change of depressive mood (≥3), logistic regression analysis was performed using the initial BDI score as the dependent variable, with age, BMI, testosterone level, initial IPSS, initial QoL, initial IIEF, and underlying disease used as the independent variables. The data are presented with mean±standard deviation and all tests were considered significant two-sided with *P*\<0.05. Statistical analyses were performed with IBM SPSS Statistics ver. 22.0 (IBM Co., Armonk, NY, USA).

RESULTS
=======

Patient characteristics are summarized in [Table 1](#t1-jer-15-2-264){ref-type="table"}. BDI level significantly decreased 3 months later, but other parameters such as testosterone, IPSS, QoL, and IIEF were not significantly different ([Table 2](#t2-jer-15-2-264){ref-type="table"}). When the target patients were divided into an older and a younger group (age ≥70 and age \<70 years), no change in BDI between initial assessment and assessment 3 months later was detected in both groups ([Table 2](#t2-jer-15-2-264){ref-type="table"}). BDI scores were related with IPSS in both initial and 3 months later (*r*=0.423, 0.429, *P*\< 0.05) ([Fig. 1](#f1-jer-15-2-264){ref-type="fig"}), however, in terms of age, BMI, underlying disease, QoL, and IIEF, there was no significant correlation (*P*\>0.05) with BDI score in either the initial assessment or 3 months later ([Table 3](#t3-jer-15-2-264){ref-type="table"}). BMI was identified as one of the risk factors to significantly decrease the probability of BDI score (≥3) (odds ratio \[OR\], 2.206; 95% confidence interval \[CI\], 1.097--4.437; *P*=0.027). The underlying disease showed a borderline *P*-value for association with BDI score (OR, 0.041; 95% CI, 0.001--1.272; *P*=0.068) and there was no significant correlation detected between decreasing BDI score (≥3) with age, testosterone, IPSS, QoL, and IIEF ([Table 4](#t4-jer-15-2-264){ref-type="table"}). In correlation analysis between BDI and each BDI subscale, sadness, self-dislike, self-criticalness, and worthlessness showed high correlation (*r*\>0.6, *P*\<0.05); this could possibly imply that these subscales are highly affected with BDI ([Table 5](#t5-jer-15-2-264){ref-type="table"}) ([Supplementary Table 1](#s1-jer-15-2-264){ref-type="supplementary-material"}).

DISCUSSION
==========

Correlation between PCa and psychopathologic status has recently been recognized; accordingly, research regarding depressive mood in PCa patients is essential, not only because of the relationship between depressive mood and patients' QoL, but also because there are some reports that depression is a meaningful predictor of survivor and mortality in PCa patients ([@b9-jer-15-2-264]; [@b25-jer-15-2-264]). Risk factors for emotional stress extend beyond the cancer diagnosis itself and include surgery-related psychotic and physical burdens and functional deterioration after surgery. For example, sexual change and LUTS are risk factors for depressive symptoms ([@b9-jer-15-2-264]). Occasionally, a higher degree of depressive symptoms at the time of diagnosis but prior to treatment may have an influence on sexual and urinary dysfunction, with the reverse association also applying ([@b15-jer-15-2-264]). As a result of all of the above factors, the importance of depressive mood in patients with PCa is expanding.

There are some reports about the relationship between depressive mood and functional deterioration ([@b10-jer-15-2-264]; [@b11-jer-15-2-264]; [@b22-jer-15-2-264]; [@b23-jer-15-2-264]; [@b26-jer-15-2-264]). Definitively, patients with severe LUTS are at a high risk of depression with increasing severity of LUTS worsening depression ([@b10-jer-15-2-264]), and higher levels of cancer-specific anxiety are related to poor sexual function ([@b26-jer-15-2-264]). However, functional impairments do not seem to be the only reason depressive symptoms occur. [@b22-jer-15-2-264] reported that despite a PCa diagnosis, and functional impairment being risk factors for mental health issues (anxiety, depressive disorder, and suicide), patients treated with RP or radiation therapy had a lower risk of developing mental health issues compared with patients undergoing watchful waiting who probably have better urinary and sexual function. So there is a need for research regarding the factors that affect depressive mood and the degree of the importance of these factors.

Another prospective study assessed anxiety and depression after a PCa diagnosis and treatment from 6-month to 5-year follow-up showed a significant and clinically meaningful improvement in mental health at 6-month follow-up ([@b11-jer-15-2-264]). The findings from this study are consistent with our findings, which showed some improvement in depressive mood 3 months after RP. From this result, it might be interpreted that the nature and cause of depressive mood of PCa patients are different in the early and the late period of treatment. Considering this, our finding raises several points for correlation and discussion with regards to research findings, which might give some clue about the characteristics of depressive mood in the early period. Each item of BDI can be summarized by its characteristics ([@b14-jer-15-2-264]). In PCa patients, feelings such as sadness, self-dislike, self-criticalness, and worthlessness could have more effect on their depressive mood ([Supplementary Table 1](#s1-jer-15-2-264){ref-type="supplementary-material"}).

There are some interesting points in which this research is different from the other studies. First, considering other reports that sexual dysfunction, urinary dysfunction, and resulting bother increased significantly over 6 months among all patients, particularly ones treated with surgery, our results that only LUTS was related to the depressive mood in the early period is quite interesting ([@b16-jer-15-2-264]). It shows that during the early period of treatment, PCa patients have minimal expectation related to sexual function. On the contrary, the presence of urinary symptoms was directly related to the depressive symptoms. Secondly, until now, many researchers have been interested in the relationship between QoL and PCa. Some studies have even recommended regular measurement of QoL as an independent prognostic factor for PCa ([@b30-jer-15-2-264]). Sexual change has been linked to the increased risk of depressive symptoms and poor QoL in studies with a longer follow-up ([@b8-jer-15-2-264]; [@b13-jer-15-2-264]). However, in the present study, there was no relationship found between lower urinary function, sexual function, depressive mood, and QoL. Another interesting finding is that functional deteriorations are not the major factor that determines the QoL in patients in the early stage after RP in localized PCa. Thirdly, in contrast with a report that younger age (\<70 years) was predictive of poorer psychopathology ([@b1-jer-15-2-264]), our report shows no difference in relation between BDI and IPSS score according to age. One possible explanation is because our study was performed within an exceptionally short period following prostatectomy compared to others. Finally, obesity was identified as a related factor that decreased depressive mood (BDI score decrease≥3), but the existence of underlying disease might also increase depressive mood.

To the best of our knowledge, this study is about the earliest tendency of changing depressive mood in PCa patients and the affecting factors but has some limitations including a short study duration and a small sample size. In terms of small sample size, the largest significant correlation in our paper is 0.429, which is slightly below the large effect of 0.50, only 30 of sample size can give us almost 0.80 of power at the 0.05 level ([@b4-jer-15-2-264]). However, further studies are required in order to establish a sound scientific basis for the determination of depressive mood in PCa patients.

Depressive mood improved significantly at the short-term follow up in patients with localized PCa after RP. Voiding symptoms were mainly related to the depressive mood; however sexual function and QoL had minimal impact on the depressive mood in the early stage. These relationships should be followed up for a longer period to ascertain the change in the pattern which could provide a better chance to support patients' emotional wellbeing and provide long-term care.
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###### 

Beck depression inventory (BDI) subscales according to their characteristics

![Association between Beck depression inventory (BDI) and international prostatic symptom score. CI, confidence interval.](jer-15-2-264f1){#f1-jer-15-2-264}

###### 

Patient characteristics (n=30)

  Demographic parameter               Value
  ----------------------------------- ------------
  Age (yr)                            68.03±6.10
                                      
  Body mass index (kg/m^2^)           25.92±2.99
                                      
  Prostate-specific antigen (ng/mL)   1.18±4.28
                                      
  Stage                               T1--2N0M0
                                      
  Underlying diseases (n)             21
   Hypertension                       17
   Diabetes mellitus                  2
   Heart disease                      4
   Other disease                      8

Values presented as mean±standard deviation or number.

###### 

Study parameters, at initial assessment and 3 months later

  Parameter             Initial         3 months later   *P*-value
  --------------------- --------------- ---------------- ----------------------------------------------------
  TST (ng/dL)           384.80±172.33   392.36±190.49    0.881
                                                         
  IPSS                  11.93±8.63      11.13±8.89       0.506
                                                         
  QoL                   2.57±2.43       2.83±1.26        0.187
                                                         
  IIEF                  3.80±3.92       3.67±3.76        0.712
                                                         
  BDI                   11.30±9.49      9.83±8.79        0.023[\*](#tfn4-jer-15-2-264){ref-type="table-fn"}
   Age \<70 yr (n=15)   9.87±7.34       8.40±6.15        0.106
   Age ≥70 yr (n=15)    12.73±11.34     11.27±10.85      0.127
   BDI guilt            0.17±0.38       0.40±0.67        0.032[\*](#tfn4-jer-15-2-264){ref-type="table-fn"}
   BDI loss energy      0.83±0.99       0.47±0.51        0.046[\*](#tfn4-jer-15-2-264){ref-type="table-fn"}

Values presented as mean±standard deviation.

TST, testosterone; IPSS, International Prostatic Symptoms Score; QoL, quality of life; IIEF, International Index of Erectile Function; BDI, Beck depression inventory.

*P*\<0.05 considered significant.

###### 

Correlation analysis between BDI & assessed parameters

                             Age     BMI      Underlying diseases   TST     IPSS                                                 QoL     IIEF
  -------------------- ----- ------- -------- --------------------- ------- ---------------------------------------------------- ------- --------
  BDI initial          *β*   0.123   0.048    0.147                 0.165   0.423[\*](#tfn6-jer-15-2-264){ref-type="table-fn"}   0.301   −0.108
                       *P*   0.518   0.805    0.437                 0.383   0.020                                                0.106   0.570
                                                                                                                                         
  BDI 3 months later   *β*   0.170   −0.076   0.181                 0.041   0.429[\*](#tfn6-jer-15-2-264){ref-type="table-fn"}   0.239   −0.081
                       *P*   0.369   0.369    0.338                 0.834   0.018                                                0.203   0.670

BDI, Beck depression inventory; BMI, body mass index; TST, testosterone; IPSS, International Prostatic Symptoms Score; QoL, quality of life; IIEF, International Index of Erectile Function.

*P*\<0.05 considered significant.

###### 

Results of logistic regression analysis for BDI score change (≥3) and independent variables

  Independent variable   OR (95% CI)             SE      *P*-value
  ---------------------- ----------------------- ------- ----------------------------------------------------
  Cons                   1.622 (5.155--50.884)   0.000   0.130
  Age                    0.890 (0.728--1.087)    0.091   0.253
  Body mass index        2.206 (1.097--4.437)    0.787   0.027[\*](#tfn8-jer-15-2-264){ref-type="table-fn"}
  TST initial            1.007 (0.996--1.019)    0.006   0.202
  IPSS initial           0.982 (0.776--1.258)    0.124   0.885
  QoL initial            1.509 (0.461--5.606)    1.010   0.539
  IIEF initial           0.483 (0.178--1.312)    0.246   0.154
  Underlying disease     0.041 (0.001--1.272)    0.072   0.068

BDI, Beck depression inventory; OR, odds ratio; CI, confidence interval; SE, standard error; TST, testosterone; IPSS, International Prostatic Symptoms Score; QoL, quality of life; IIEF, International Index of Erectile Function.

*P*\<0.05 considered significant.

###### 

Correlation analysis between BDI & subscales with high correlation (*r* \>0.6, *P*\<0.05)

                       BDI subscale (n)                           
  -------------------- ------------------ ------- ------- ------- -------
  BDI initial          *β*                0.653   0.691   0.749   0.754
  *P*                  0.001              0.001   0.012   0.001   
                                                                  
  BDI 3 months later   *β*                0.629   0.681   0.737   0.693
  *P*                  0.001              0.001   0.001   0.001   

BDI, Beck depression inventory.
